Nerandomilast in Patients with Progressive Pulmonary Fibrosis
Toby M. Maher(Imperial College London), Fernando J. Martínez(University of Michigan–Ann Arbor), Justin M. Oldham(University of Michigan), Vincent Cottin(Université Claude Bernard Lyon 1), Luca Richeldi, Shervin Assassi(The University of Texas Health Science Center at Houston), Carl Coeck(Royal Brompton & Harefield NHS Foundation Trust), Marlies Wijsenbeek(Erasmus University Rotterdam), Florian Voß(Boehringer Ingelheim (Germany)), Arata Azuma, Claudia Valenzuela(Hospital Universitario de La Princesa), Donald F. Zoz(Boehringer Ingelheim (United States)), Gerrit Weimann(Bayer (United States)), Susanne Stowasser(Royal Brompton & Harefield NHS Foundation Trust), Heng Gu(Chinese Academy of Medical Sciences Dermatology Hospital), Emmanuelle Clerisme-Beaty(Royal Brompton & Harefield NHS Foundation Trust), Ivana Ritter(Boehringer Ingelheim (Germany)), Michael Kreuter(Johannes Gutenberg University Mainz), Anna‐Maria Hoffmann‐Vold(Oslo University Hospital)
Cited by 134
Related Papers
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper
|European Respiratory Journal|2004|4.4k
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2018|4.1k
Clinical Characteristics of Covid-19 in New York City
|New England Journal of Medicine|2020|2.4k
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
|New England Journal of Medicine|2019|2.3k